Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans

Charles C. Weige, Marc R. Birtwistle, Himel Mallick, Nengjun Yi, Zuzana Berrong, Emily Cloessner, Keely Duff, Josephine Tidwell, Megan Clendenning, Brent Wilkerson, Christopher Farrell, Fred Bunz, Hao Ji, Michael Shtutman, Kim E. Creek, Carolyn E. Banister, Phillip J. Buckhaults

Research output: Contribution to journalArticle

Abstract

African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele-speci fic gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53 Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele- specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1b (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1b silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity.

Original languageEnglish (US)
Pages (from-to)1029-1041
Number of pages13
JournalMolecular Cancer Research
Volume12
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Transcriptome
African Americans
Colonic Neoplasms
Small Interfering RNA
Alleles
Neoplasms
Cell Differentiation
Gene Silencing
Gene Expression Profiling
Etoposide
RNA Interference
Epigenomics
Individuality
Codon
Libraries
Chromatin
Single Nucleotide Polymorphism
Colon
Stem Cells
Genotype

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Weige, C. C., Birtwistle, M. R., Mallick, H., Yi, N., Berrong, Z., Cloessner, E., ... Buckhaults, P. J. (2014). Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Molecular Cancer Research, 12(7), 1029-1041. https://doi.org/10.1158/1541-7786.MCR-13-0286-T

Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. / Weige, Charles C.; Birtwistle, Marc R.; Mallick, Himel; Yi, Nengjun; Berrong, Zuzana; Cloessner, Emily; Duff, Keely; Tidwell, Josephine; Clendenning, Megan; Wilkerson, Brent; Farrell, Christopher; Bunz, Fred; Ji, Hao; Shtutman, Michael; Creek, Kim E.; Banister, Carolyn E.; Buckhaults, Phillip J.

In: Molecular Cancer Research, Vol. 12, No. 7, 2014, p. 1029-1041.

Research output: Contribution to journalArticle

Weige, CC, Birtwistle, MR, Mallick, H, Yi, N, Berrong, Z, Cloessner, E, Duff, K, Tidwell, J, Clendenning, M, Wilkerson, B, Farrell, C, Bunz, F, Ji, H, Shtutman, M, Creek, KE, Banister, CE & Buckhaults, PJ 2014, 'Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans', Molecular Cancer Research, vol. 12, no. 7, pp. 1029-1041. https://doi.org/10.1158/1541-7786.MCR-13-0286-T
Weige, Charles C. ; Birtwistle, Marc R. ; Mallick, Himel ; Yi, Nengjun ; Berrong, Zuzana ; Cloessner, Emily ; Duff, Keely ; Tidwell, Josephine ; Clendenning, Megan ; Wilkerson, Brent ; Farrell, Christopher ; Bunz, Fred ; Ji, Hao ; Shtutman, Michael ; Creek, Kim E. ; Banister, Carolyn E. ; Buckhaults, Phillip J. / Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. In: Molecular Cancer Research. 2014 ; Vol. 12, No. 7. pp. 1029-1041.
@article{60037f224d89477f84be01a35da5e67f,
title = "Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans",
abstract = "African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51{\%} vs. 37{\%}), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele-speci fic gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53 Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele- specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1b (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1b silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity.",
author = "Weige, {Charles C.} and Birtwistle, {Marc R.} and Himel Mallick and Nengjun Yi and Zuzana Berrong and Emily Cloessner and Keely Duff and Josephine Tidwell and Megan Clendenning and Brent Wilkerson and Christopher Farrell and Fred Bunz and Hao Ji and Michael Shtutman and Creek, {Kim E.} and Banister, {Carolyn E.} and Buckhaults, {Phillip J.}",
year = "2014",
doi = "10.1158/1541-7786.MCR-13-0286-T",
language = "English (US)",
volume = "12",
pages = "1029--1041",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans

AU - Weige, Charles C.

AU - Birtwistle, Marc R.

AU - Mallick, Himel

AU - Yi, Nengjun

AU - Berrong, Zuzana

AU - Cloessner, Emily

AU - Duff, Keely

AU - Tidwell, Josephine

AU - Clendenning, Megan

AU - Wilkerson, Brent

AU - Farrell, Christopher

AU - Bunz, Fred

AU - Ji, Hao

AU - Shtutman, Michael

AU - Creek, Kim E.

AU - Banister, Carolyn E.

AU - Buckhaults, Phillip J.

PY - 2014

Y1 - 2014

N2 - African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele-speci fic gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53 Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele- specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1b (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1b silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity.

AB - African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele-speci fic gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53 Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele- specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1b (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1b silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity.

UR - http://www.scopus.com/inward/record.url?scp=84904248339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904248339&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-13-0286-T

DO - 10.1158/1541-7786.MCR-13-0286-T

M3 - Article

C2 - 24743655

AN - SCOPUS:84904248339

VL - 12

SP - 1029

EP - 1041

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 7

ER -